Loading...
Cancer immunotherapy insights: key takeaways from the ADSCC bone marrow and cellular therapy congress 2024
Formigo, Gisela Maria Suárez Mazorra, Zaima Olexen, Cinthia Menéndez, Tamara Hadi, Loubna Abdel Handgretinger, Rupert Hernandez, Antonio Alfonso Bencomo Najjar, Inas El Coukos, George Sabzevari, Helen
Formigo, Gisela Maria Suárez
Mazorra, Zaima
Olexen, Cinthia
Menéndez, Tamara
Hadi, Loubna Abdel
Handgretinger, Rupert
Hernandez, Antonio Alfonso Bencomo
Najjar, Inas El
Coukos, George
Sabzevari, Helen
Author
Formigo, Gisela Maria Suárez
Mazorra, Zaima
Olexen, Cinthia
Menéndez, Tamara
Hadi, Loubna Abdel
Handgretinger, Rupert
Hernandez, Antonio Alfonso Bencomo
Najjar, Inas El
Coukos, George
Sabzevari, Helen
Bollard, Catherine
Couriel, Daniel
Wald, David
Hamieh, Mohamad
Briones, Javier
AlKaabi, Fatima
Ventura-Carmenate, Yendry
Mazorra, Zaima
Olexen, Cinthia
Menéndez, Tamara
Hadi, Loubna Abdel
Handgretinger, Rupert
Hernandez, Antonio Alfonso Bencomo
Najjar, Inas El
Coukos, George
Sabzevari, Helen
Bollard, Catherine
Couriel, Daniel
Wald, David
Hamieh, Mohamad
Briones, Javier
AlKaabi, Fatima
Ventura-Carmenate, Yendry
Supervisor
Department
Personalized Medicine
Embargo End Date
Type
Review
Date
License
http://creativecommons.org/licenses/by/4.0/
Language
English
Collections
Research Projects
Organizational Units
Journal Issue
Abstract
The rising global cancer burden underscores the urgent need for innovative and effective therapies. Molecular and cellular immunology advances have revolutionized cancer immunotherapy, transforming laboratory discoveries into clinical breakthroughs. The Second Bone Marrow Transplant and Cellular Therapy Congress, held in Abu Dhabi, United Arab Emirates (UAE), on October 26<sup>th</sup> - 27<sup>th</sup>, 2024, and sponsored by the Abu Dhabi Stem Cells Center (ADSCC), convened global experts to discuss cutting-edge developments in adoptive cell transfer (ACT); chimeric antigen receptor T-cell (CAR-T) therapy, tumor-infiltrating lymphocyte (TIL) engineering and T-cell receptor (TCR) innovations. Discussions covered key challenges such as tumor microenvironment (TME) resistance, antigen escape, manufacturing complexity, cost-effectiveness, and accessibility. Experts emphasized the crucial role of biomarker identification in optimizing patient selection and improving treatment efficacy. Additionally, emerging strategies were highlighted to enhance the durability and specificity of cellular therapies, including next-generation CAR-T designs, combination approaches, and novel gene-editing technologies. With over 2,300 participants from academia, research, and healthcare, the event fostered international collaborations and knowledge exchange. The ADSCC continues to play a pivotal role in integrating advanced cellular therapies into healthcare systems, contributing to the expansion of precision oncology in the UAE and beyond. This review analyzes the latest advances in immunotherapy, highlighting their clinical impact, challenges, and future directions in the evolving landscape of cancer treatment, as debated during the congress.
Citation
G.M.S. Formigo, Z. Mazorra, C. Olexen, T. Menéndez, L.A. Hadi, R. Handgretinger , et al., "Cancer immunotherapy insights: key takeaways from the ADSCC bone marrow and cellular therapy congress 2024," Frontiers in Immunology, vol. 16, pp. 1650023-1650023, 2026, https://doi.org/10.3389/fimmu.2025.1650023.
Source
Frontiers in Immunology
Conference
Keywords
32 Biomedical and Clinical Sciences, 3204 Immunology, 3211 Oncology and Carcinogenesis, Animals, Bone Marrow Transplantation, Cell- and Tissue-Based Therapy, Congresses as Topic, Humans, Immunotherapy, Immunotherapy, Adoptive, Lymphocytes, Tumor-Infiltrating, Neoplasms, Receptors, Chimeric Antigen, Tumor Microenvironment, 3 Good Health and Well Being
Subjects
Source
Publisher
Frontiers